257 related articles for article (PubMed ID: 27064686)
1. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.
He F; Warlick E; Miller JS; MacMillan M; Verneris MR; Cao Q; Weisdorf D
Bone Marrow Transplant; 2016 Aug; 51(8):1107-12. PubMed ID: 27064686
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.
de Lima M; Bonamino M; Vasconcelos Z; Colares M; Diamond H; Zalcberg I; Tavares R; Lerner D; Byington R; Bouzas L; da Matta J; Andrade C; Carvalho L; Pires V; Barone B; Maciel C; Tabak D
Bone Marrow Transplant; 2001 Jan; 27(1):73-8. PubMed ID: 11244440
[TBL] [Abstract][Full Text] [Related]
3. Successful remission rates and survival after lymphodepleting chemotherapy and donor lymphocyte infusion for relapsed hematologic malignancies postallogeneic hematopoietic cell transplantation.
Warlick ED; DeFor T; Blazar BR; Burns L; Verneris MR; Ustun C; Weisdorf DJ; Miller JS
Biol Blood Marrow Transplant; 2012 Mar; 18(3):480-6. PubMed ID: 22155141
[TBL] [Abstract][Full Text] [Related]
4. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors.
Yan CH; Liu DH; Xu LP; Liu KY; Zhao T; Wang Y; Chen H; Chen YH; Han W; Huang XJ
Clin Transplant; 2012; 26(6):868-76. PubMed ID: 22432715
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Liver graft-versus-host disease after donor lymphocyte infusion for relapses of hematologic malignancies post allogeneic hematopoietic stem cell transplantation.
Ma SY; Au WY; Lie AK; Ng IO; Leung AY; Tse EW; Liang RH; Lau GK; Kwong YL
Bone Marrow Transplant; 2004 Jul; 34(1):57-61. PubMed ID: 15156162
[TBL] [Abstract][Full Text] [Related]
7. Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT.
Yan CH; Xu LP; Liu DH; Chen H; Wang Y; Wang JZ; Wang FR; Han W; Liu KY; Huang XJ
Clin Transplant; 2015 Jul; 29(7):594-605. PubMed ID: 25969866
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2017 May; 96(5):829-838. PubMed ID: 28285386
[TBL] [Abstract][Full Text] [Related]
9. Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft.
Hasskarl J; Zerweck A; Wäsch R; Ihorst G; Bertz H; Finke J
Bone Marrow Transplant; 2012 Feb; 47(2):277-82. PubMed ID: 21460873
[TBL] [Abstract][Full Text] [Related]
10. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study.
Rampotas A; Sockel K; Panitsas F; Theuser C; Bornhauser M; Hernani R; Hernandez-Boluda JC; Esquirol A; Avenoso D; Tsirigotis P; Robin M; Czerw T; Helbig G; Roddie C; Lambert J; McLornan DP
Transplant Cell Ther; 2023 Nov; 29(11):687.e1-687.e7. PubMed ID: 37633414
[TBL] [Abstract][Full Text] [Related]
11. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.
Introna M; Lussana F; Algarotti A; Gotti E; Valgardsdottir R; Micò C; Grassi A; Pavoni C; Ferrari ML; Delaini F; Todisco E; Cavattoni I; Deola S; Biagi E; Balduzzi A; Rovelli A; Parma M; Napolitano S; Sgroi G; Marrocco E; Perseghin P; Belotti D; Cabiati B; Gaipa G; Golay J; Biondi A; Rambaldi A
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2070-2078. PubMed ID: 28712935
[TBL] [Abstract][Full Text] [Related]
12. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM
Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276
[TBL] [Abstract][Full Text] [Related]
13. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125
[TBL] [Abstract][Full Text] [Related]
14. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity.
Guillaume T; Gaugler B; Chevallier P; Delaunay J; Ayari S; Clavert A; Rialland F; Le Gouill S; Blin N; Gastinne T; Mahé B; Dubruille V; Moreau P; Mohty M
Bone Marrow Transplant; 2012 Aug; 47(8):1112-7. PubMed ID: 22120986
[TBL] [Abstract][Full Text] [Related]
15. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
16. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
[TBL] [Abstract][Full Text] [Related]
17. Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter.
Ros-Soto J; Snowden JA; Szydlo R; Nicholson E; Madrigal A; Easdale S; Potter M; Ethell M; Anthias C
Transplant Cell Ther; 2022 Apr; 28(4):183.e1-183.e8. PubMed ID: 35104660
[TBL] [Abstract][Full Text] [Related]
18. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy.
Goldsmith SR; Slade M; DiPersio JF; Westervelt P; Schroeder MA; Gao F; Romee R
Bone Marrow Transplant; 2017 Dec; 52(12):1623-1628. PubMed ID: 29035393
[TBL] [Abstract][Full Text] [Related]
19. [Prophylactic G-CSF mobilized donor lymphocytes infusion after non-myeloablative stem cell transplantation prevents relapse in patients with high-risk leukemia].
Zhao HX; Sun WJ; Li J; Qiao JX; Huang YJ; Hu HL; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):922-5. PubMed ID: 24294845
[TBL] [Abstract][Full Text] [Related]
20. Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Huang XJ; Jiang Q; Chen H; Xu L; Liu D; Chen Y; Han W; Zhang Y; Liu K; Lu D
Bone Marrow Transplant; 2005 Aug; 36(4):343-8. PubMed ID: 15968295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
